HUP0203521A2 - Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása - Google Patents

Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása

Info

Publication number
HUP0203521A2
HUP0203521A2 HU0203521A HUP0203521A HUP0203521A2 HU P0203521 A2 HUP0203521 A2 HU P0203521A2 HU 0203521 A HU0203521 A HU 0203521A HU P0203521 A HUP0203521 A HU P0203521A HU P0203521 A2 HUP0203521 A2 HU P0203521A2
Authority
HU
Hungary
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
preparation
Prior art date
Application number
HU0203521A
Other languages
English (en)
Hungarian (hu)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle Robinson Brostrom
Derek Lawrence Tickner
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0203521A2 publication Critical patent/HUP0203521A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
HU0203521A 1999-11-30 2000-11-14 Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása HUP0203521A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (1)

Publication Number Publication Date
HUP0203521A2 true HUP0203521A2 (hu) 2003-02-28

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203521A HUP0203521A2 (hu) 1999-11-30 2000-11-14 Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása

Country Status (28)

Country Link
EP (1) EP1246804A1 (ru)
JP (1) JP2003515592A (ru)
KR (1) KR20020058057A (ru)
CN (1) CN1402711A (ru)
AP (1) AP2002002531A0 (ru)
AU (1) AU1048801A (ru)
BG (1) BG106854A (ru)
BR (1) BR0015836A (ru)
CA (1) CA2392979A1 (ru)
CO (1) CO5271716A1 (ru)
EA (1) EA200200510A1 (ru)
EC (1) ECSP003792A (ru)
EE (1) EE200200277A (ru)
GT (1) GT200000199A (ru)
HU (1) HUP0203521A2 (ru)
IL (1) IL149097A0 (ru)
IS (1) IS6338A (ru)
MA (1) MA26845A1 (ru)
MX (1) MXPA02005354A (ru)
NO (1) NO20022558L (ru)
OA (1) OA12099A (ru)
PA (1) PA8506301A1 (ru)
PE (1) PE20010904A1 (ru)
PL (1) PL355892A1 (ru)
TN (1) TNSN00231A1 (ru)
TR (1) TR200201446T2 (ru)
UY (1) UY26454A1 (ru)
WO (1) WO2001040190A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
PT1533292E (pt) 2002-08-30 2007-05-31 Japan Tobacco Inc Compostos de dibenzilamina e sua utilização farmacêutica.
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1622872A1 (en) * 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
EP1653927B1 (en) 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CN1863778A (zh) 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
CA2562082C (en) * 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
RU2007135224A (ru) 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
KR102456013B1 (ko) 2014-07-30 2022-10-18 에프. 호프만-라 로슈 아게 고밀도 지질단백질(hdl)-상승 제제 또는 hdl-모방 제제에 의한 치료법에 대한 반응성을 예측하기 위한 유전 표지

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
PL355892A1 (en) 2004-05-31
BG106854A (bg) 2002-12-29
EA200200510A1 (ru) 2002-10-31
WO2001040190A1 (en) 2001-06-07
TR200201446T2 (tr) 2002-11-21
EP1246804A1 (en) 2002-10-09
NO20022558D0 (no) 2002-05-29
IS6338A (is) 2002-04-12
AU1048801A (en) 2001-06-12
JP2003515592A (ja) 2003-05-07
UY26454A1 (es) 2001-07-31
CN1402711A (zh) 2003-03-12
ECSP003792A (es) 2002-04-23
KR20020058057A (ko) 2002-07-12
IL149097A0 (en) 2002-11-10
PA8506301A1 (es) 2002-08-26
GT200000199A (es) 2002-05-23
AP2002002531A0 (en) 2002-06-30
CO5271716A1 (es) 2003-04-30
CA2392979A1 (en) 2001-06-07
MA26845A1 (fr) 2004-12-20
MXPA02005354A (es) 2002-12-11
TNSN00231A1 (fr) 2002-05-30
OA12099A (en) 2006-05-04
PE20010904A1 (es) 2001-09-10
NO20022558L (no) 2002-05-29
BR0015836A (pt) 2002-08-06
EE200200277A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
HUP0203521A2 (hu) Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása
HUP0303084A2 (hu) Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0002987A2 (hu) Cefdinir diciklohexil-amin sója és eljárás a só előállítására valamint a vegyület sójából történő felszabadítására
HUP0302519A2 (hu) Az atorvasztatin kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0102813A2 (hu) Perindopril-terc-butil-amin-só új béta-kristályos formája, eljárás ennek előállítására és ezt tartalmazó gyógyászati készítmények
IL150482A0 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
ATE240316T1 (de) Heteroaromatische amide als inhibitoren von faktor xa
PT915898E (pt) Forma i cristalina de claritromicina
MXPA02011425A (es) Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa.
HUP0302475A2 (hu) Eljárás allergia kezelésére szubsztituált pirazolok alkalmazásával
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
HUP0301076A2 (hu) Linezolid II kristályforma és előállítása
HUP0303034A2 (hu) Új 7-azaindol-származékok, foszfodiészteráz-4 inhibitorjakénti alkalmazásuk és eljárás az előállításukra
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
HUP0302479A2 (hu) NF-kappa B gátló gyógyszerkészítmény, amely hatóanyagként helyettesített benzoesavszármazékot tartalmaz
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények
HUP0402602A2 (hu) Eljárás echinokandin-származékok előállítására, ezek alkalmazása, ezeket tartalmazó gyógyszerkészítmények és intermedierek
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
NO20010559D0 (no) Fremgangsmåte for syntese av (1H)-benzo[c]kinolizin-3-ones derivater
HUP0401234A2 (hu) Pravastatin stabil gyógyászati kompozíciója és eljárás az előállítására
HUP0303760A2 (hu) AZ NF-kB faktort gátló szubsztituált benzoesavszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0102447A2 (hu) Új oktahidro-6,10-dioxo-6H-piridazino[1,2-a][1,2]diazepin-1-karbonsav-származékok, eljárás a vegyületek előállítására és alkalmazásuk gyógyászati hatóanyagok előállítására
DE60019157D1 (de) Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit
HUP0203270A2 (hu) Hidroxánsav-származék mint a humán CD23 termelés inhibitora, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények és alkalmazásuk